Weekly Digest - April 2024

Weekly Digest - April 2024

8 Apr 2024: Genmab to acquire ADC maker ProfoundBio

  • Genmab to acquire ProfoundBio for $1.8 billion
  • Acquisition includes three clinical-stage drug candidates:
    • Rinatabart sesutecan targets folate receptor α in ovarian cancer and solid tumors
    • PRO1160 targets CD70 in kidney, nasopharyngeal cancers, and non-Hodgkin’s lymphoma
    • PRO1107 targets PTK7 in solid tumors
  • Genmab will inherit ProfoundBio’s ADC development platforms

For full story click here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home